Department of Abdominal Surgery, Vilnius City Clinical Hospital, 57 Antakalnio Str., LT-10207 Vilnius, Lithuania.
Faculty of Medicine, Vilnius University, LT-08412 Vilnius, Lithuania.
Int J Mol Sci. 2022 May 27;23(11):6040. doi: 10.3390/ijms23116040.
According to current guidelines, the current treatment for locally advanced rectal cancer is neoadjuvant therapy, followed by a total mesorectal excision. However, radiosensitivity tends to differ among patients due to tumor heterogeneity, making it difficult to predict the possible outcomes of the neoadjuvant therapy. This review aims to investigate different types of tissue-based biomarkers and their capability of predicting tumor response to neoadjuvant therapy in patients with locally advanced rectal cancer. We identified 169 abstracts in NCBI PubMed, selected 48 reports considered to meet inclusion criteria and performed this systematic review. Multiple classes of molecular biomarkers, such as proteins, DNA, micro-RNA or tumor immune microenvironment, were studied as potential predictors for rectal cancer response; nonetheless, no literature to date has provided enough sufficient evidence for any of them to be introduced into clinical practice.
根据当前的指南，局部晚期直肠癌的当前治疗方法是新辅助治疗，然后进行全直肠系膜切除术。然而，由于肿瘤异质性，患者的放射敏感性往往存在差异，因此难以预测新辅助治疗的可能结果。本综述旨在探讨不同类型的基于组织的生物标志物及其预测局部晚期直肠癌患者对新辅助治疗的肿瘤反应的能力。我们在 NCBI PubMed 中确定了 169 篇摘要，选择了 48 篇被认为符合纳入标准的报告，并进行了这项系统综述。多种分子生物标志物，如蛋白质、DNA、micro-RNA 或肿瘤免疫微环境，被研究为直肠癌反应的潜在预测因子；然而，迄今为止，没有任何文献提供足够的证据将它们中的任何一种引入临床实践。
Zotero 插件